These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Imatinib--a new perspective in the treatment of tumors]. Klener P; Klamová H Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894 [TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumors and the evolution of targeted therapy. Sanborn RE; Blanke CD Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051 [TBL] [Abstract][Full Text] [Related]
8. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Gross DJ; Munter G; Bitan M; Siegal T; Gabizon A; Weitzen R; Merimsky O; Ackerstein A; Salmon A; Sella A; Slavin S; Endocr Relat Cancer; 2006 Jun; 13(2):535-40. PubMed ID: 16728580 [TBL] [Abstract][Full Text] [Related]
9. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs]. Shiba K; Matsumoto T; Hirota S Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796 [TBL] [Abstract][Full Text] [Related]
10. [Clinical studies with imatinib in 2004]. Eckhardt S Orv Hetil; 2005 May; 146(18 Suppl 1):941-4. PubMed ID: 15921309 [TBL] [Abstract][Full Text] [Related]
11. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520 [TBL] [Abstract][Full Text] [Related]
12. [Imatinib]. Urabe A Gan To Kagaku Ryoho; 2003 Aug; 30(8):1191-6. PubMed ID: 12938280 [TBL] [Abstract][Full Text] [Related]
13. Imatinib: a targeted clinical drug development. Capdeville R; Silberman S Semin Hematol; 2003 Apr; 40(2 Suppl 2):15-20. PubMed ID: 12783370 [TBL] [Abstract][Full Text] [Related]